All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Anas Younes is a Professor of Medicine at the Weill-Cornell Medical College, and the Special Advisor to the Chairman of Medicine for Research and the Steven A. Greenberg Chair in Lymphoma Research at the Memorial Sloan Kettering Cancer Center New York, US.
Educated at the Faculty of Medicine, Damascus University, Damascus, SY, Prof. Younes then went on to complete his residencies at the College of Medicine at the University of Toledo, Toledo, US, and at the SUNY Downstate Medical Center, Brooklyn, US. He then made the short move over to Memorial Sloan Kettering Cancer Center, New York, US, to complete his hematology-oncology fellowship.
In 1992, following his fellowship, Prof. Younes worked at The University of Texas MD Anderson Cancer Center, Houston, US, where he acted as a clinical researcher and treating physician for the next two decades. In 2013, Prof. Younes made the move back east to become the Chief of Lymphoma Service at the Memorial Sloan Kettering Cancer Center.
With particular interest in both non-Hodgkin and Hodgkin lymphomas, Prof. Younes works towards the development of novel targeted therapies for lymphoma, as well as the identification of biomarkers for treatment. He has been the Principal Investigator in over 60 clinical trials, including some of the pivotal trials around nivolumab and brentuximab vedotin in relapsed/refractory Hodgkin lymphoma, which resulted in FDA approvals.
Positions of responsibility/awards: